Document:

SUBSCRIPTION AGREEMENT JUNE 5, 2001

 

 EXHIBIT 10.36

 

SUBSCRIPTION AGREEMENT

 

        SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereof between
Bioject Medical Technologies Inc., an Oregon corporation (the “Company”) and the undersigned (the “Subscriber”).

 

WITNESSETH:

 

        WHEREAS, the Company is offering in a private placement to the Subscriber (the “Offering”) 130,000 shares of
its common stock, no par value (the “Common Stock”) at a price equal to $10.00 per share (the “Offering Price”), and warrants to purchase shares of Common Stock equal to fifteen percent (15%) of the total number of shares sold to
the Subscriber in the Offering at an exercise price per share equal to $13.50 (the “Warrants”). The Warrants are issued for a five (5) year period. The shares of Common Stock and Warrants offered hereby are sometimes referred to as the
“Securities;” and

 

        WHEREAS, the Subscriber desires to purchase that number of Securities set forth on the signature page hereof on the
terms and conditions hereinafter set forth; and

 

        WHEREAS, the Company has engaged Leerink Swann & Company (the “Placement Agent”) as placement agent for
the Offering on a “best-efforts” basis.

 

        NOW, THEREFORE, in consideration of the premises and the mutual representations and covenants hereinafter set forth, the
parties hereto agree as follows:

 

I.    SUBSCRIPTION FOR SECURITIES AND REPRESENTATIONS BY SUBSCRIBER

 

        1.1    Subject to the terms and conditions hereinafter set forth, the Subscriber hereby irrevocably
subscribes for and agrees to purchase from the Company such Securities as is set forth upon the signature page hereof and the Company agrees to sell such Securities to the Subscriber for said purchase price. The purchase price is payable by personal
or business check, wire transfer of immediately available funds or money order made payable to First Union National Bank, Corporate Trust Administration, 10 State House Square, 2nd Floor, Hartford, CT 06103, Reference: Account 95728356081, First
Union National Bank as Escrow Agent for Bioject Medical Technology Escrow contemporaneously with the execution and delivery of this Agreement by the Subscriber. All wires should be sent to:

 

		 First Union National Bank

		 Charlotte, NC

		 ABA# 053 000 219

		 Credit a/c: 5000000016439 Trust Ops

		 For further credit to a/c: 95728356081 First Union National Bank as Escrow Agent for Bioject Medical Technology Inc
Escrow

		 Attn: CT9750

 

        Certificates for the shares of Common Stock and the Warrants will be delivered by the Company to the Subscriber promptly
following the Closing (as herein defined).

 

        1.2    The Subscriber recognizes that the purchase of Securities involves a high degree of risk in
that (i) the Company remains a development stage business with a limited operating history and may require substantial funds in addition to the proceeds of the Offering; (ii) an investment in the Company is highly speculative and only investors who
can afford the loss of their entire investment should consider investing in the Company; (iii) the Subscriber may not be able to liquidate its investment; (iv) transferability of the Securities is extremely limited; and (v) in the event of a
disposition, the Subscriber could sustain the loss of its entire investment.

 

 

 

         1.3    The Subscriber represents that the Subscriber is an “accredited investor” as such
term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended, (the “Act”), as indicated by the responses to the questions contained in Section VII hereof, and that the Subscriber is able to bear the
economic risk and illiquidity of an investment in the Securities.

 

        1.4    The Subscriber hereby acknowledges and represents that (i) the Subscriber has prior
investment experience, including investment in non-listed and unregistered securities, or that the Subscriber has employed the services of an investment advisor, attorney and/or accountant to read all of the documents furnished or made available by
the Company both to the Subscriber and to all other prospective investors to evaluate the merits and risks of such an investment on the Subscriber’s behalf; (ii) the Subscriber recognizes the highly speculative nature of an investment in the
Securities; and (iii) the Subscriber is able to bear the economic risk and illiquidity which the Subscriber assumes by investing in the Securities.

 

        1.5    The Subscriber (i) hereby acknowledges receipt and careful review of the Memorandum dated
May, 2001 (the “Memorandum”), and to the extent that specific filings of the Company with the SEC (as herein defined) under the Act or the Exchange Act (as herein defined) and exhibits thereto have not been specifically included in such
package, the Subscriber hereby acknowledges that it has had a reasonable opportunity to review such filings on the SEC’s EDGAR database or otherwise (the Memorandum and all of the foregoing filings and exhibits of the Company are referred to
herein as the “Offering Package”); (ii) hereby represents that the Subscriber has been furnished by the Company during the course of this transaction with all information regarding the Company which the Subscriber has requested or desired
to know; (iii) has been afforded the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company concerning the terms and conditions of the Offering; and (iv) has received any additional
information which the Subscriber has requested. The Subscriber acknowledges that the Memorandum was delivered solely for informational purposes and does not set forth the terms of the Offering.

 

        1.6    (a)    In making the decision to invest in the Securities, the Subscriber
has relied solely upon the information provided by the Company in the Offering Package. To the extent necessary, the Subscriber has retained, at its own expense, and relied upon the advice of appropriate professionals regarding the investment, tax
and legal merits and consequences of this Agreement and its purchase of the Securities hereunder. The Subscriber acknowledges and agrees that the Placement Agent has not supplied any information for inclusion in the Offering Package other than
information furnished in writing to the Company by the Placement Agent specifically for inclusion in the Offering Package relating to the Placement Agent, that the Placement Agent has no responsibility for the accuracy or completeness of the
Offering Package and that the Subscriber has not relied upon the independent investigation or verification, if any, which may have been undertaken by the Placement Agent.

 

                (b)    The Subscriber represents that (i) the
Subscriber was contacted regarding the sale of the Securities by the Placement Agent (or an authorized agent or representative thereof) with whom the Subscriber had a prior substantial pre-existing relationship and (ii) no Securities were offered or
sold to it by means of any form of general solicitation or general advertising, and in connection therewith the Subscriber did not (A) receive or review any advertisement, article, notice or other communication published in a newspaper or magazine
or similar media or broadcast over television or radio, whether closed circuit or generally available; or (B) attend any seminar, meeting or industry investor conference whose attendees were invited by any general solicitation or general
advertising.

 

        1.7    The Subscriber hereby acknowledges that the Offering has not been reviewed by the United
States Securities and Exchange Commission (the “SEC”) because of the Company’s representations that this Offering is intended to be exempt from the registration requirements of Section 5 of the Act pursuant to Sections 3(b), 4(2) and
4(6) thereof and Regulation D promulgated under the Act. The Subscriber agrees that the Subscriber will not sell or otherwise transfer the Securities unless they are registered under the Act or unless an exemption from such registration is
available.

 

2

 

         1.8    The Subscriber understands that none of the Securities have been registered under the Act by
reason of a claimed exemption under the provisions of the Act which depends, in part, upon the Subscriber’s investment intention. In this connection, the Subscriber hereby represents that the Subscriber is purchasing the Securities for the
Subscriber’s own account for investment and not with a view toward the resale or distribution thereof to others. The Subscriber, if an entity, was not formed for the purpose of purchasing the Securities. The Subscriber understands that Rule 144
promulgated under the Act requires, among other conditions, a one-year holding period prior to the resale (in limited amounts) of securities acquired in a non-public offering without having to satisfy the registration requirements under the
Act.

 

        1.9    The Subscriber understands and hereby acknowledges that the Company is under no obligation to
register the Securities under the Act or any state securities or “blue sky” laws other than as set forth in Section V. The Subscriber consents that the Company may, if it desires, permit the transfer of the Securities out of the
Subscriber’s name only when the Subscriber’s request for transfer is accompanied by an opinion of counsel reasonably satisfactory to the Company that neither the sale nor the proposed transfer results in a violation of the Act or any
applicable state “blue sky” laws (collectively, “Securities Laws”).

 

        1.10    The Subscriber consents to the placement of a legend on any certificate or other document
evidencing the Securities indicating that such Securities have not been registered under the Act or any state securities or “blue sky” laws and setting forth or referring to the restrictions on transferability and sale thereof contained in
this Agreement. The Subscriber is aware that the Company will make a notation in its appropriate records and issue “stop transfer” instructions to its transfer agent with respect to the restrictions on the transferability of such
Securities.

 

        1.11    The Subscriber understands that the Company will review this Agreement and, if such
Subscriber is an individual, hereby gives authority to the Company to call Subscriber’s bank or place of employment (in a call in which the Placement Agent participates) or otherwise review the financial standing of the Subscriber; and it is
further agreed that upon their mutual agreement the Placement Agent and the Company reserve the unrestricted right, without further documentation or agreement on the part of the Subscriber, to reject or limit any subscription, to accept
subscriptions for Securities and to close the Offering to the Subscriber at any time.

 

        1.12    The Subscriber hereby represents that the address of the Subscriber furnished by the
Subscriber on the signature page hereof is the Subscriber’s principal residence if the Subscriber is an individual or its principal business address if it is a corporation or other entity.

 

        1.13    The Subscriber represents that the Subscriber has full power and authority (corporate,
statutory and otherwise) to execute and deliver this Agreement and to purchase the Securities subscribed for hereby. This Agreement constitutes the legal, valid and binding obligation of the Subscriber, enforceable against the Subscriber in
accordance with its terms.

 

        1.14    If the Subscriber is a corporation, partnership, limited liability company, trust, employee
benefit plan, individual retirement account, Keogh Plan, or other entity, then (a) it is authorized and qualified to become an investor in the Company and the person signing this Agreement on behalf of such entity has been duly authorized by such
entity to do so, and (b) it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.

 

        1.15    The Subscriber acknowledges that if he or she is a registered representative of a National
Association of Securities Dealers, Inc. (“NASD”) member firm, he or she must give such firm the notice required by the NASD’s Rules of Fair Practice, receipt of which must be acknowledged by such firm in Section 7.4 below.

 

        1.16    The Subscriber represents and warrants that it has not engaged, consented to nor authorized
any broker, finder or intermediary to act on its behalf, directly or indirectly, as a broker, finder or intermediary in connection with the transactions contemplated by this Agreement. The Subscriber shall indemnify and hold harmless the Company
from and against all fees, commissions or other payments owing to any such person or firm acting on behalf of such Subscriber hereunder.

 

3

 

         1.17    The Subscriber acknowledges that (a) the Company has engaged, consented to and authorized
the Placement Agent in connection with the transactions contemplated by this Agreement, (b) the Company shall pay the Placement Agent a commission and reimburse the Placement Agent’s expenses in accordance with the Placement Agency Agreement
(as defined in Section 5.1(c) below), and the Company shall indemnify and hold harmless the Subscriber from and against all fees, commissions or other payments owing by the Company to the Placement Agent or any other person or firm acting on behalf
of the Company hereunder and (c) registered representatives of the Placement Agent and/or its designees (including, without limitation, registered representatives of the Placement Agent and/or its designees who participate in the Offering and sale
of the securities sold in the Offering) will be paid a portion of the commissions paid to the Placement Agent including a portion of the Placement Warrants (as defined in Section 5.1(c) below).

 

        1.18    The Subscriber, whose name appears on the signature line below, shall be the beneficial
owner of the Securities for which such Subscriber subscribes.

 

        1.19    The Subscriber agrees that from the time the Subscriber first received the Offering Package
until a point in time equal to the earlier of (i) the date that the Registration Statement (as defined in Section 5.2(a)) is declared effective by the SEC or (ii) four months from the date of the Offering Package, the Subscriber has not and shall
not, directly or indirectly, through related parties, affiliates or otherwise, (A) sell “short” or “short against the box” (as those terms are generally understood) any equity security of the Company or (B) otherwise engage in
any transaction that involves hedging of the Subscriber’s position in any equity security of the Company.

 

II.    REPRESENTATIONS BY THE COMPANY

 

        The Company hereby represents and warrants to the Subscriber that:

 

        2.1    Organization and Qualification.    The Company is a corporation
duly organized and validly existing under the laws of the State of Oregon and has full corporate power and lawful authority to conduct its business as described in the Offering Package. The Company is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction in which the nature of the business conducted, or as proposed to be conducted in the Offering Package, by it or the properties owned, leased or operated by it, makes such qualification or
licensing necessary and where the failure to be so qualified or licensed would have a material adverse effect upon the business, prospects or financial condition of the Company.

 

        2.2    Capitalization and Voting Rights.    The authorized, issued and
outstanding capital stock of the Company is as set forth in the Offering Package; all issued and outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable. Except as set forth in the Offering Package, there
are no outstanding options, warrants, agreements, commitments, convertible securities, preemptive rights or other rights to subscribe for or to purchase any shares of capital stock of the Company nor are there any agreements, promises or commitments
to issue any of the foregoing, or discussions concerning same. Except as set forth in the Offering Package, in this Agreement and as otherwise required by law, there are no restrictions upon the voting or transfer of the Securities pursuant to the
Company’s Articles of Incorporation, as amended, (the “Articles of Incorporation”), By-laws or other governing documents or any agreement or other instruments to which the Company is a party or by which the Company is
bound.

 

        2.3    Authorization; Enforceability.    The Company has all corporate
right, power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the authorization, execution, delivery and
performance of this Agreement by the Company, the authorization, sale, issuance and delivery of the Securities and the performance of the Company’s obligations hereunder has been taken. This Agreement has been duly executed and delivered by the
Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules
of law governing specific performance, injunctive relief or other equitable remedies, and to limitations of public policy. The Securities have been duly and validly authorized

 

4

 and, upon the issuance and delivery thereof and payment therefor as contemplated by this Agreement, will be free and clear of liens, duly and validly authorized and
issued, fully paid and nonassessable. The issuance and sale of the Securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person.

 

        2.4    No Conflict; Governmental Consents.

 

                (a)    The execution and delivery by the Company of
this Agreement, the consummation of the transactions contemplated hereby and the offer and sale of the Securities will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or
governmental authority to or by which the Company is bound, or of any provision of the Articles of Incorporation or By-laws of the Company, and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or
constitute (with due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company is a party or by which it is bound or to which any
of its properties or assets is subject, nor result in the creation or imposition of any lien upon any of the properties or assets of the Company.

 

                (b)    No consent, waiver, approval, authorization
or other order of any governmental authority or other third-party is required to be obtained by the Company in connection with the authorization, execution and delivery of this Agreement or with the authorization, issuance and sale of the
Securities, except such filings as may be required to be made, and which shall have been made at or prior to the required time (except with respect to the Notification Form: Listing of Additional Shares with Nasdaq), with the SEC, the NASD and the
National Association of Securities Dealers Automated Quotation System SmallCap Market (“Nasdaq”), and with any state or foreign blue sky or securities regulatory authority.

 

        2.5    Licenses.    Except as may be set forth in the Offering Package,
the Company has all licenses, permits and other governmental authorizations currently required for the conduct of its business or ownership of properties and is in all material respects complying therewith, except for any licenses, permits or other
governmental authorizations which would not materially adversely affect the business, property, financial condition, results of operations or prospects of the Company.

 

        2.6    Litigation.    The Company knows of no pending or threatened legal
or governmental proceedings against the Company which could materially adversely affect the business, property, financial condition, results of operations or prospects of the Company.

 

        2.7    Accuracy of Reports.    All reports required to be filed by the
Company within the three years prior to the date of this Agreement under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), have been duly and timely filed with the SEC, complied at the time of filing in all material
respects with the requirements of their respective forms and, were complete and correct in all material respects as of the dates at which the information was furnished, and contained (as of such dates) no untrue statement of a material fact or
omitted to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 

        2.8    Accuracy of Offering Package.    No information set forth in the
Offering Package contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 

        2.9    Investment Company.    The Company is not an “investment
company” within the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

        2.10    Listing.    The Company will file a Notification Form: Listing of
Additional Shares with the Nasdaq SmallCap Market and hereby represents and warrants to the Placement Agent and the Subscriber that it will take

 

5

 any other necessary action in accordance with the rules of the Nasdaq SmallCap Market to enable the Securities (and the Common Stock issuable upon exercise of the
Placement Warrants as defined in Section 5.1 (c)) to trade on the Nasdaq SmallCap Market.

 

        2.11    No Material Adverse Change.    Since the filing of the
Company’s most recent Quarterly Report on Form 10-Q, (i) there has not been any material adverse change (financial or otherwise) in the assets, properties, financial condition, operating results or business of the Company, and (ii) there has
been no event or condition of any character that might have a material adverse effect (financial or otherwise) in the assets, properties, financial condition, operating results or business of the Company.

 

        2.12    Financial Statements.    The financial statements included in the
Company’s most recent Annual Report on Form 10-K, as amended, for the fiscal year ended March 31, 2000 and all other reports filed by the Company pursuant to the Exchange Act since the filing of such Annual Report on Form 10-K, as amended, and
prior to the date hereof (collectively, the “SEC Filings”) present fairly and accurately in all material respects the financial position of the Company as of the dates shown and its results of operations and cash flows for the periods
shown, and such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis. Except as set forth in the financial statements of the Company included in the SEC Filings filed prior
to the date hereof, to the best of the Company’s knowledge, the Company has no liabilities, contingent or otherwise, except those which individually or in the aggregate are not material to the financial condition or operating results of the
Company.

 

        2.13    Compliance with Laws.    Neither the Company nor, to the
Company’s knowledge, any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D of the Act) in connection with the offer or sale of the Securities. Neither the Company
nor any of its Affiliates, nor, to the Company’s knowledge, any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that
would adversely affect reliance by the Company on Section 4(2) of the Act for the exemption from registration for the transactions contemplated hereby or would require registration of the Securities under the Act. The Company is in compliance with
all applicable Nasdaq continued listing requirements. There are no proceedings pending or to the Company’s knowledge threatened against the Company relating to the continued listing of the Company’s Common Stock on the Nasdaq SmallCap
Market and the Company has not received any notice of, nor to the knowledge of the Company is there any basis for, the delisting of the Common Stock from the Nasdaq SmallCap Market.

 

III.    TERMS OF SUBSCRIPTION

 

        3.1    The Offering is for 130,000 shares of Common Stock and Warrants. The Securities are offered
on a “best efforts” basis.

 

        3.2    Upon the mutual consent of the Company and the Placement Agent, this Offering may close (the
“Closing”) upon the sale of all 130,000 shares of Common Stock. The Closing shall occur at the discretion of the Company and the Placement Agent (the “Closing Date”). The purchase price is payable by personal or business check,
wire transfer of immediately available funds or money order made payable as provided in Section 1.1.

 

        3.3    The Subscriber hereby authorizes and directs the Company to deliver the Securities to be
issued to the Subscriber pursuant to this Agreement directly to the Subscriber’s account maintained by the Placement Agent or, if no such account exists, to the residential or business address indicated on the signature page hereto.

 

        3.4    The Subscriber hereby authorizes and directs the Company to return any funds related to
unaccepted subscriptions to the same account from which the funds were drawn, including any customer account maintained with the Placement Agent.

 

6

 

 IV.    CONDITIONS TO OBLIGATIONS OF THE SUBSCRIBERS AND THE COMPANY

 

        4.1    The Subscribers’ obligation to purchase the Securities at the Closing is subject to the
fulfillment on or prior to the Closing Date of the following conditions, which conditions may be waived at the option of each Subscriber to the extent permitted by law:

 

                (a)    Representations and Warranties.
    The representations and warranties made by the Company in Section II hereof shall be true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing Date with the
same force and effect as if they had been made on and as of said date.

 

                (b)    Covenants.    All
covenants, agreements and conditions contained in this Agreement to be performed by the Company on or prior to such purchase shall have been performed or complied with in all material respects.

 

                (c)    No Legal Order Pending. 
   There shall not then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement.

 

                (d)    No Law Prohibiting or Restricting Such
Sale.    There shall not be in effect any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval of any person to issue the Securities which consent or approval shall not have been
obtained (except as may otherwise be provided in this Agreement).

 

                (e)    Legal Opinion.   
 Upon the Closing, counsel to the Company shall have delivered to the Placement Agent for the benefit of the Subscribers a legal opinion with respect to such legal matters relating to this Agreement and the Offering Package as the Placement
Agent may reasonably require.

 

        4.2    The Company’s obligation to sell the Securities at the Closing is subject to the
fulfillment on or prior to the Closing Date of the following conditions, which conditions may be waived at the option of the Company to the extent permitted by law:

 

                (a)    Acknowledgements, Representations and
Warranties.    The acknowledgements, representations and warranties made by the Subscriber in Section I hereof shall be true and correct in all material respects when made, and shall be true and correct in all material
respects on the Closing Date with the same force and effect as if they had been made on and as of said date. If any such representations, warranties or acknowledgements shall not be true and accurate in any respect prior to the Closing, the
undersigned shall give immediate written notice of such fact to the Company, to the Placement Agent, and to his representatives, if any, specifying which representations, warranties or acknowledgements are not true and accurate and the reason
therefor.

 

                (b)    Covenants.    All
covenants, agreements and conditions contained in this Agreement to be performed by the Subscriber on or prior to such purchase shall have been performed or complied with in all material respects.

 

                (c)    No Legal Order Pending. 
   There shall not then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement.

 

                (d)    No Law Prohibiting or Restricting Such
Sale.    There shall not be in effect any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval of any person to issue the Securities which consent or approval shall not have been
obtained (except as may otherwise be provided in this Agreement).

 

V.    REGISTRATION RIGHTS

 

        5.1    As used in this Agreement, the following terms shall have the following meanings:

 

                (a)    “Affiliate” shall mean, with
respect to any Person (as defined below), any other Person controlling, controlled by, or under direct or indirect common control with, such Person (for the purposes of this

 

7

 definition “control,” when used with respect to any specified Person, shall mean the power to direct the management and policies of such person, directly or
indirectly, whether through ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” shall have meanings correlative to the foregoing).

 

                (b)    “Business Day” shall mean a
day, Monday through Friday, on which banks are generally open for business in each of New York, New York; Boston, Massachusetts; and Portland, Oregon.

 

                (c)    “Holders” shall mean the
Subscriber and any person holding Registrable Securities as defined below (including the Registrable Securities underlying the warrants to be issued to the Placement Agent (the “Placement Warrants”) to be granted to the Placement Agent
and/or their designees pursuant to the engagement letter between the Company and the Placement Agent dated                       
             [March 14, 2001], (the “Placement Agency Agreement”)), a holder of the Placement Warrants, or any person to whom the rights under Section V have been transferred
in accordance with Section 5.10 hereof, and who, if known by the Company, shall be specifically named by the Company as selling stockholders in the Registration Statement (as defined below).

 

                (d)    “Person” shall mean any
person, individual, corporation, limited liability company, partnership, trust or other nongovernmental entity or any governmental agency, court, authority or other body (whether foreign, federal, state, local or otherwise).

 

                (e)    The terms “register,”
“registered” and “registration” refer to the registration effected by preparing and filing with the SEC a registration statement in compliance with the Act, and the declaration or ordering by the SEC of the
effectiveness of such registration statement.

 

                (f)    “Registrable Securities”
shall mean (i) the Common Stock (ii) the shares of Common Stock issuable upon the exercise of the Warrants, and (iii) shares of Common Stock issuable upon the exercise of the Placement Warrants; provided, however, that securities shall only be
treated as Registrable Securities if and only for so long as they (A) have not been disposed of pursuant to a registration statement declared effective by the SEC, (B) have not been sold in a transaction exempt from the registration and prospectus
delivery requirements of the Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale, and (C) are held by a Holder or a permitted transferee pursuant to Section
5.10.

 

                (g)    “Registration Expenses”
shall mean all expenses incurred by the Company in complying with Section 5.2 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and expenses of counsel for the Company, blue
sky fees and expenses and the expense of any special audits incident to, or required by, any such registration (but excluding the aggregate fees of legal counsel for all Holders).

 

                (h)    “Registration Statement”
shall have the meaning ascribed to such term in Section 5.2 (a).

 

                (i)    “Registration Period” shall
have the meaning ascribed to such term in Section 5.4 (a).

 

                (j)    “Selling Expenses” shall
mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and the aggregate fees and expenses of legal counsel for all Holders.

 

        5.2    (a)    The Company shall, as soon as practicable, but not later than
thirty (30) business days after the Closing Date (the “Filing Date”), (i) use its best efforts to file with the SEC a registration statement on Form S-3 (or if not eligible for such form, on such other form on which the Company is
eligible) (the “Registration Statement”) with respect to the resale of the Registerable Securities and use its best efforts to have such Registration Statement declared effective by the SEC as soon thereafter as is practical and (ii) cause
such Registration Statement to remain effective for the Registration Period.

 

                (b)    If the Registration Statement is not filed on
or prior to the Filing Date, then for each successive thirty (30) day period beyond the Filing Date, the Company shall pay to each Subscriber, in cash, as liquidated

 

8

 damages and not as a penalty, one percent (1%) of the aggregate purchase price previously paid by such Subscriber for Securities (or a pro rata amount for any
periods less than thirty (30) days) until such time as the filing is made; provided, however, such Subscriber shall not be entitled to such cash payment if and to the extent that such delays are the result of the failure of such
Subscriber to provide the Company with written information necessary to complete the Registration Statement by the Filing Date.

 

        5.3    All Registration Expenses incurred in connection with any registration, qualification,
exemption or compliance pursuant to Section 5.2 shall be borne by the Company. All Selling Expenses relating to the sale of securities registered by or on behalf of Holders shall be borne by such Holders pro rata on the basis of the number of
securities so registered.

 

        5.4    In the case of the registration, qualification, exemption or compliance effected by the
Company pursuant to this Agreement, the Company shall, upon reasonable request, inform each Holder as to the status of such registration, qualification, exemption and compliance. At its expense the Company shall:

 

                (a)    use its best efforts to keep such
registration, and any qualification, exemption or compliance under state securities laws which the Holders reasonably request the Company to obtain, continuously effective as to all Registrable Securities until the Holders have completed the
distribution described in the registration statement relating thereto. The period of time during which the Company is required hereunder to keep the Registration Statement effective is referred to herein as “the Registration Period.”
Notwithstanding the foregoing, at the Company’s election, the Company may cease to keep such registration, qualification, exemption or compliance effective with respect to any Registrable Securities, and the registration rights of a Holder with
respect to such Registrable Securities shall expire, at such time as the Holder may sell all Registrable Securities then held by such Holder under Rule 144 under the Act in a three-month period, but this sentence shall not relieve the Company of any
obligation to comply with this Section V as to any shares of Common Stock issuable upon exercise of the Placement Warrants;

 

                (b)    advise the Holders (or in the case of (ii)
below, to advise the Placement Agent):

 

                        (i)  
  when the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective amendment thereto has become effective;

 

                        (ii)  
  of any request by the SEC for amendments or supplements to the Registration Statement or the prospectus included therein or for additional information;

 

                        (iii)  
  of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for such purpose;

 

                        (iv)  
  of the receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such
purpose; and

 

                        (v)  
  subject to the limitations set forth in Section 5.7(b)(ii) hereof, of the happening of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such date, the statements therein are
not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of the prospectus, in the light of the circumstances under which they were made) not
misleading;

 

                (c)    make every reasonable effort to obtain the
withdrawal of any order suspending the effectiveness of any Registration Statement at the earliest possible time;

 

                (d)    furnish to each Holder, without charge, at
least one copy of such Registration Statement and any post-effective amendment or supplement thereto, including financial statements and schedules, and, if the Holder so requests in writing, all exhibits (excluding those incorporated by reference)
in the form filed with the SEC;

 

9

 

                 (e)    during the Registration Period, deliver to
each Holder, without charge, a reasonable number of copies of the prospectus included in such Registration Statement and any amendment or supplement thereto as such Holder may reasonably request; and the Company consents to the use, consistent with
the provisions hereof, of the prospectus and any amendment or supplement thereto by each of the selling Holders of Registrable Securities in connection with the offering and sale of the Registrable Securities covered by the prospectus and any
amendment or supplement thereto;

 

                (f)    during the Registration Period, deliver to
each Holder, without charge, (i) as soon as practicable (but in the case of the annual report of the Company to its stockholders, within 120 days after the end of each fiscal year of the Company) one copy of: (A) its annual report to its
stockholders, if any (which annual report shall contain financial statements audited in accordance with generally accepted accounting principles in the United States of America by a firm of certified public accountants of recognized standing); (B)
if not included in substance in its annual report to stockholders, its annual report on Form 10-K (or similar form); (C) a copy of the full Registration Statement (excluding exhibits); (ii) upon reasonable request, all exhibits excluded by the
parenthetical to the immediately preceding clause (C); and (iii) such other documents as may be reasonably requested.

 

                (g)    prior to any public offering of Registrable
Securities pursuant to the Registration Statement, register or qualify or obtain an exemption for the offer and sale under the securities or blue sky laws of such jurisdictions as any such Holders reasonably request in writing, provided that the
Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction, and do any
and all other acts or things reasonably necessary or advisable to enable the offer and sale in such jurisdictions of the Registrable Securities covered by the Registration Statement;

 

                (h)    cooperate with the Holders to facilitate the
timely preparation and delivery of certificates representing Registrable Securities to be sold pursuant to the Registration Statement free of any restrictive legends to the extent not required at such time and in such denominations and registered in
such names as Holders may request at least five (5) business days prior to sales of Registrable Securities pursuant to the Registration Statement;

 

                (i)    upon the occurrence of any event contemplated
by Section 5.4(b)(v) above, the Company shall promptly prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of
the Registrable Securities included therein, the prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; and

 

                (j)    use its best efforts to comply with all
applicable rules and regulations of the SEC, and make generally available to the Holders not later than 45 days (or 90 days if the fiscal quarter is the fourth fiscal quarter) after the end of its fiscal quarter in which the first anniversary date
of the effective date of the Registration Statement occurs, an earnings statement satisfying the provisions of Section 11(a) of the Act.

 

        5.5    The Holders shall have no right to take any action to restrain, enjoin or otherwise delay any
registration pursuant to Section 5.2 hereof as a result of any controversy that may arise with respect to the interpretation or implementation of this Agreement.

 

        5.6    (a)    To the extent permitted by law, the Company shall indemnify each
Holder, each underwriter of the Registrable Securities and each person controlling such Holder and each such underwriter within the meaning of Section 15 of the Act, with respect to which any registration, qualification or compliance has been sought
pursuant to this Agreement, against all claims, losses, expenses, costs, damages and liabilities (or action in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to Section
5.6(c) below), arising out of or based on (i) any untrue statement (or alleged untrue statement)

 

10

 of a material fact contained in any registration statement, prospectus or offering circular, or any amendment or supplement thereof, incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances in which they were
made, or (ii) any violation or alleged violation by the Company of the Act, the Exchange Act, or any rule or regulation promulgated under the Act or the Exchange Act, and shall reimburse each Holder, each underwriter of the Registrable Securities
and each person controlling such Holder and each such underwriter, for reasonable legal and other expenses, in connection with investigating or defending any such claim, loss, damage, liability or action as and when incurred; provided that the
Company shall not be liable in any such case to the extent that any untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder or
underwriter and stated to be specifically for use in preparation of such registration statement, prospectus or offering circular; provided that the Company shall not be liable in any such case where the claim, loss, damage or liability arises out of
or is related to the failure of the Holder to comply with the covenants and agreements contained in Section 5.7 hereof, and except that the foregoing indemnity agreement is subject to the condition that, insofar as it relates to any such untrue
statement or alleged untrue statement or omission or alleged omission made in the preliminary prospectus but eliminated or remedied in the amended prospectus on file with the SEC at the time the registration statement becomes effective or in the
amended prospectus filed with the SEC pursuant to Rule 424(b) of the Act or in the prospectus subject to completion under Rule 434 of the Act, which together meet the requirements of Section 10(a) of the Act (the “Final Prospectus”), such
indemnity agreement shall not inure to the benefit of any such Holder, any such underwriter or any such controlling person, if a copy of the Final Prospectus furnished by the Company to the Holder for delivery was not furnished to the person or
entity asserting the loss, liability, claim or damage at or prior to the time such furnishing is required by the Act and the Final Prospectus would have cured the defect giving rise to such loss, liability, claim or damage. Notwithstanding any
provision herein to the contrary, the Company shall reimburse each Holder, upon such Holder’s demand, for all reasonably necessary expenses and costs which are incurred, as and when incurred, by such Holder as a result of the indemnification
claims described in this Section 5.6(a). Such demand may be made from time to time prior to resolution of the claim. In no event shall the Company be liable for the expenses and costs of more than one attorney on behalf of the Holders unless in the
reasonable judgement of a Holder, based upon written advice of its counsel, a conflict of interest exists between the Holders with respect to such claims, in which case the Company shall reimburse the Holders for additional attorneys.

 

                (b)    Each Holder will severally, if Registrable
Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter of the Registrable Securities and
each person who controls the Company and each underwriter of the Registrable Securities within the meaning of Section 15 of the Act, against all claims, losses, expenses, costs, damages and liabilities (or actions in respect thereof), including any
of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to Section 5.6(c) below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration
statement, prospectus or offering circular, or any amendment or supplement thereof, incident to any such registration, qualification or compliance or based on any omission (or alleged omission) to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading in light of the circumstances in which they were made, and will reimburse the Company, such directors and officers, each underwriter of the Registrable Securities and each person
controlling the Company and each underwriter of the Registrable Securities for reasonable legal and any other expenses or costs reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action as
incurred, in each case to the extent, but only to the extent, that such untrue statement or omission or allegation thereof is made in reliance upon, and in conformity with, written information furnished to the Company by or on behalf of the Holder
and stated to be specifically for use in preparation of such registration statement, prospectus or offering circular; provided that the indemnity shall not apply to the extent that such claim, loss, damage or liability results from the fact that a
current copy of the prospectus or offering circular was not made available to the Holder and such current copy of the prospectus or offering circular would have cured the defect giving rise to such loss, claim,

 

11

 expense, costs, damage or liability. Notwithstanding the foregoing, in no event shall a Holder be liable for any such claims, losses, expenses, costs, damages or
liabilities in excess of the proceeds received by such Holder in that offering, except in the event of fraud by such Holder.

 

                (c)    Each party entitled to indemnification under
this Section 5.6 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which
indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense with its own counsel at such Indemnified Party’s expense unless the named
parties to any proceeding covered hereby (including any impleaded parties) include both the Company or any others the Company may designate and one or more Indemnified Persons, and representation of the Indemnified Persons and such other parties by
the same counsel would be inappropriate due to actual or potential differing interests between them, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Agreement, unless such failure is materially prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party shall not be liable for any settlement of an action or claim effected without its
written consent (which consent will not be unreasonably withheld).

 

                (d)    If the indemnification provided for in this
Section 5.6 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, cost or expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, cost or expense in such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage, cost or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied or which should have been supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission.

 

        5.7    (a)    Subject to the limitations set forth in Section 5.7(b)(ii) below,
upon receipt of any notice from the Company of the happening of any event requiring the preparation of a supplement or amendment to a prospectus relating to Registrable Securities so that, as thereafter delivered to the Holders, such prospectus will
not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, each Holder shall forthwith discontinue disposition of Registrable
Securities pursuant to the registration statement contemplated by Section 5.2 until its receipt of copies of the supplemented or amended prospectus from the Company and, if so directed by the Company, each Holder shall deliver to the Company all
copies, other than permanent file copies then in such Holder’s possession, of the prospectus covering such Registrable Securities current at the time of receipt of such notice.

 

                (b)    Any Holder which owns five percent (5%) or
more (and with respect to 5.7(b)(ii), “any Holder”) of the Company’s outstanding Common Stock shall suspend, upon request of the Company, any disposition of Registrable Securities pursuant to the Registration Statement and prospectus
contemplated by Section 5.2 during (i) any period not to exceed one 180-day period within any one 12-month period the Company requires in connection with an underwritten offering of equity securities and (ii) any period, not to exceed two 45-day
periods within any twelve month period, when the Company determines in good faith that offers and sales pursuant thereto should not be made by reason of the presence of material undisclosed circumstances or developments with respect to which the
disclosure that would be required in such a prospectus is premature, would have an adverse effect on the Company or is otherwise inadvisable.

 

12

 

                 (c)    As a condition to the inclusion of its
Registrable Securities, each Holder shall furnish to the Company such information regarding such Holder, the securities of the Company owned beneficially or of record by such Holder and the distribution proposed by such Holder as the Company may
request in writing because it is required in connection with any registration, qualification or compliance referred to in this Section V.

 

                (d)    With respect to any sale of Registrable
Securities pursuant to a Registration Statement filed pursuant to this Section V, each Holder hereby covenants with the Company not to make any sale of the Registrable Securities without effectively causing the prospectus delivery requirements under
the Act to be satisfied.

 

                (e)    Each Holder acknowledges and agrees that the
Registrable Securities sold pursuant to the Registration Statement described in this Section are not transferable on the books of the Company unless the stock certificate submitted to the transfer agent evidencing such Registrable Securities is
accompanied by a certificate reasonably satisfactory to the Company to the effect that (i) the Registrable Securities have been sold in accordance with such Registration Statement and (ii) the requirement of delivering a current prospectus has been
satisfied.

 

                (f)    Each Holder shall not take any action with
respect to any distribution deemed to be made pursuant to such registration statement, which would constitute a violation of Regulation M under the Exchange Act or any other applicable rule, regulation or law.

 

                (g)    At the end of the period during which the
Company is obligated to keep the Registration Statement current and effective as described above, the Holders of Registrable Securities included in the Registration Statement and the shares underlying the Placement Warrants shall discontinue sales
of shares pursuant to such Registration Statement upon receipt of notice from the Company of its intention to remove from registration the shares covered by such Registration Statement which remain unsold.

 

        5.8    With a view to making available to the Holders the benefits of certain rules and regulations
of the SEC which at any time permit the sale of the Registrable Securities to the public without registration, the Company shall use its reasonable best efforts:

 

                (a)    to make and keep public information
available, as those terms are understood and defined in Rule 144 under the Act, at all times;

 

                (b)    to file with the SEC in a timely manner all
reports and other documents required of the Company under the Exchange Act; and

 

                (c)    so long as a Holder owns any Registrable
Securities, to furnish to such Holder upon any reasonable request a written statement by the Company as to its compliance with Rule 144 under the Act, and of the Exchange Act, and a copy of the most recent annual or quarterly report of the Company,
and such other reports and documents of the Company as such Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing a Holder to sell any such securities without registration.

 

        5.9    With the written consent of the Company and the Holders holding a majority of the
Registerable Securities that are then outstanding, any provision of this Section V may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely) or
amended. Upon the effectuation of each such waiver or amendment, the Company shall promptly give written notice thereof to the Holders, if any, who have not previously received notice thereof or consented thereto in writing.

 

        5.10    The rights and obligations of the Holders under this Section V may not be assigned or
transferred to or assumed by any transferee or assignee except (i) to a transferee that acquires at least 20% of such Holder’s Registerable Securities or (ii) to an Affiliate or limited or general partner of a Holder; provided that such
transfer was not in violation of this Agreement or the Securities Laws.

 

13

 

 VI.    MISCELLANEOUS

 

        6.1    Any notice or other communication given hereunder shall be deemed sufficient in writing and
sent by (a) telecopy or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received); or (b) registered or certified mail, return receipt requested, or
delivered by hand against written receipt therefor, addressed to Bioject Medical Technologies Inc., 7620 S.W. Bridgeport Road, Portland, Oregon 97224, Facsimile: (503) 620-6431, Attention: James C. O’Shea, with a copy to Leerink Swann &
Company, 60 State Street, 15th Floor, Boston, Massachusetts 02019, Facsimile (617) 918-4724, Attention: Stuart R. Barich. Notices shall be deemed to have been given or delivered on the date of mailing, except notices of change of address, which
shall be deemed to have been given or delivered when received.

 

        6.2    Except as set forth in Section 5.9, this Agreement shall not be changed, modified or amended
except by a writing signed by the parties to be charged, and this Agreement may not be discharged except by performance in accordance with its terms or by a writing signed by the party to be charged.

 

        6.3    Upon the execution and delivery of this Agreement by the Subscriber, this Agreement shall
become a binding obligation of the Subscriber with respect to the purchase of Securities as herein provided, subject to acceptance by the Company and the Placement Agent; subject, however, to the right hereby reserved to the Company to enter into
the same agreements with other subscribers and to add and/or delete other persons as subscribers.

 

        6.4    Notwithstanding the place where this Agreement may be executed by any of the parties hereto,
the parties expressly agree that all the terms and provisions hereof shall be construed in accordance with and governed by the laws of the State of Oregon without regard to principles of conflicts of law.

 

        6.5    The holding of any provision of this Agreement to be invalid or unenforceable by a court of
competent jurisdiction shall not affect any other provision of this Agreement, which shall remain in full force and effect. If any provision of this Agreement shall be declared by a court of competent jurisdiction to be invalid, illegal or incapable
of being enforced in whole or in part, such provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law and the remaining conditions and provisions or portions thereof shall
nevertheless remain in full force and effect and enforceable to the extent they are valid, legal and enforceable, and no provisions shall be deemed dependent upon any other covenant or provision unless so expressed herein.

 

        6.6    It is agreed that a waiver by either party of a breach of any provision of this Agreement
shall not operate, or be construed, as a waiver of any subsequent breach by that same party.

 

        6.7    The parties agree to execute and deliver all such further documents, agreements and
instruments and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

 

        6.8    This Agreement may be executed in two or more counterparts each of which shall be deemed an
original, but all of which shall together constitute one and the same instrument.

 

        6.9    The Subscriber agrees not to issue any public statement with respect to the Subscriber’s
investment or proposed investment in the Company or the terms of any agreement or covenant between them and the Company without the Company’s prior written consent, except such disclosures as may be required under applicable law or under any
applicable order, rule or regulation.

 

        6.10    Nothing in this Agreement shall create or be deemed to create any rights in any person or
entity not a party to this Agreement, except for the holders of Registrable Securities.

 

        6.11    Any pronoun herein shall include all genders and/or the plural or singular as appropriate
from the context.

 

14

 

 VII.    CONFIDENTIAL INVESTOR QUESTIONNAIRE

 

        7.1    The Subscriber represents and warrants that he, she or it comes within one category marked
below, and that for any category marked, he, she or it has truthfully set forth, where applicable, the factual basis or reason the Subscriber comes within that category. ALL INFORMATION IN RESPONSE TO THIS SECTION VII WILL BE KEPT STRICTLY
CONFIDENTIAL. The undersigned agrees to furnish any additional information which the Company deems necessary in order to verify the answers set forth below.

 

	 Category A

		 —   The undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net
worth with his or her spouse, presently exceeds $1,000,000.

 

Explanation.    In calculating net worth you may include equity in personal property and real estate, including your principal residence, cash,
short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.

	

 

	 Category B

		 —   The undersigned is an individual (not a partnership, corporation, etc.) who had an individual income in excess of
$200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including foreign income, tax exempt income and full amount of capital gains and losses but excluding
any income of other family members and any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.

	

 

	 Category C

		 —   The undersigned is a director or executive officer of the Company.

	

 

	 Category D

		 —   The undersigned is a bank; a savings and loan association; insurance company; registered investment company;
registered business development company; licensed small business investment company or “SBIC”; or employee benefit plan within the meaning of Title 1 of Employee Retirement Income Security Act or “ERISA” and (a) the investment
decision is made by a plan fiduciary which is either a bank, savings and loan association, insurance company or registered investment advisor, or (b) the plan has total assets in excess of $5,000,000 or is a self-directed plan with investment
decisions made solely by persons that are accredited investors.

 

 

 

(describe entity)

	

 

	 Category E

		 —   The undersigned is a private business development company as defined in section 202(a)(22) of the Investment
Advisors Act of 1940.

 

 

 

(describe entity)

	

 

	 Category F

		 —   The undersigned is either a corporation, partnership, Massachusetts business trust, or nonprofit organization within
the meaning of Section 501(c)(3) of the Internal Revenue Code, in each case not formed for the specific purpose of acquiring the Securities and with total assets in excess of $5,000,000.

 

 

 

(describe entity)

	

 

15

 

	  Category G

		 —   The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of
acquiring the Securities where the purchase is directed by a “sophisticated person” as defined in Regulation 506(b)(2)(ii) under the Act.

	

 

	 Category H

		 —   The undersigned hereby certifies that it is an accredited investor because all of its equity owners are accredited
investors. The Company, in its sole discretion, may request information regarding the basis on which such equity owners are accredited.

	

 

	 Category I

		 —   The undersigned hereby certifies that it is an accredited investor because it has total assets in excess of
$5,000,000 and was not formed for the specific purpose of acquiring the Securities.

	

 

	 Category J

		 —   The undersigned is not within any of the categories above and is therefore not an accredited investor.

	

 

The Company will notify a prospective Subscriber whether such Subscriber is eligible to purchase Securities pursuant to this Agreement (and the Company, in its sole
discretion, retains the right to accept or reject all such purchases). The undersigned agrees that it will notify the Company at any time on or prior to the Closing Date in the event that the representations and warranties in this Investor
Questionnaire shall cease to be true, accurate and complete.

 

        7.2    SUITABILITY (please answer each question)

 

(a)    For an individual Subscriber, please describe your current employment, including the company by which you are employed and its principal
business:

 

 

 

 

 

 

 

(b)    For an individual Subscriber, please describe any college or graduate degrees held by you:

 

 

 

 

 

 

 

(c)    For all Subscribers, please list types of prior investments:

 

 

 

 

 

 

 

16

 

 (d)    For all Subscribers, please state whether you have participated in other private placements before:

 

	YES	  	                    
	    	NO	  	                    

 

(e)    If your answer to question (d) above was “YES”, please indicate frequency of such prior participation in private placements
of:

 

	 	    	Public

Companies
	    	Private

Companies
	    	Biotechnology,

Pharmaceutical

and Other

Life Science

Companies *

	Frequently	    	                	    	                	    	                
	  	  	
	  	
	  	

	Occasionally	    	                	    	                	    	                
	  	  	
	  	
	  	

	Never	    	                	    	                	    	                
	  	  	
	  	
	  	

 

		*

	 indicate how many companies, whether public or private, are in the biotechnology, pharmaceutical or other life
sciences sectors.

 

(f)    For an individual Subscriber, do you expect your current level of income to significantly decrease in the foreseeable future?

 

	YES	  	                    
	    	NO	  	                    

 

(g)    For trust, corporate, partnership and other institutional Subscribers, do you expect your total assets to significantly decrease in the
foreseeable future?

 

	YES	  	                    
	    	NO	  	                    

 

(h)    For all Subscribers, do you have any other investments or contingent liabilities which you reasonably anticipate could cause you to need
sudden cash requirements in excess of cash readily available to you?

 

	YES	  	                    
	    	NO	  	                    

 

(i)    For all Subscribers, are you familiar with the risk aspects and the non-liquidity of investments such as the securities for which you seek to
subscribe?

 

	YES	  	                    
	    	NO	  	                    

 

(j)    For all Subscribers, do you understand that there is no guarantee of financial return on this investment and that you run the risk of losing
your entire investment?

 

	YES	  	                    
	    	NO	  	                    

 

        7.3    MANNER IN WHICH TITLE IS TO BE HELD. (circle one)

 

                (a)    Individual Ownership

                (b)    Community Property

                (c)    Joint Tenant with Right of Survivorship (both
parties must sign)

                (d)    Partnership*

                (e)    Tenants in Common

                (f)    Company*

                (g)    Trust*

                (h)    Other

 

        *If Securities are being subscribed for by an entity, the attached Certificate of Signatory must also be
completed.

 

17

 

         7.4    NASD AFFILIATION.

 

Are you affiliated or associated with an NASD member firm (please check one)?

 

	YES	  	                    
	    	NO	  	                    

 

If yes, please describe:**

 

 

 

 

 

        **If Subscriber is a Registered Representative with an NASD member firm, have the following acknowledgment signed by
the appropriate party:

 

        The undersigned NASD member firm acknowledges receipt of the notice required by Article 3, Sections 28(a) and (b) of the
Rules of Fair Practice.

 

		 

 

		 Name of NASD Member Firm

 

		 By: 

 

		 Authorized Officer—Signature

 

		 

 

		 Authorized Officer—Printed Name

 

		 Date:                  
                                        
          , 2001

 

        7.5    STOCK OWNERSHIP

 

Do you beneficially own any shares of the Company’s Common Stock or any securities convertible into or exercisable for shares of the Company’s Common
Stock?

 

	YES	  	                    
	    	NO	  	                    

 

If yes, please describe, including number of shares:

 

 

 

 

 

        7.6    COMPANY RELIANCE ON THIS QUESTIONNAIRE

 

The undersigned is informed of the significance to the Company of the foregoing representations and answers contained in this Section VII and such answers have been
provided under the assumption that the Company and its counsel will rely on them.

 

18

 

	  SIGNATURE PAGE

		 Date Signed:                  
                                   , 2001

	

 

	 Number of shares:

		     

		 130,000                    
        

	

 

	 Multiplied by Offering Price per share:

		 x

		 $10.00

	

 

	 Equals subscription amount:

		 =

		 $1,300,000

	

 

  

Warrants (multiply the number of shares by 15%):    195,000

 

  

    

	 

 

Signature

 

 

Printed Name

 

 

Entity Name

 

 

Address

 

 

City, State and Zip Code

 

 

Telephone—Business

 

 

Facsimile—Business

 

 

Tax ID # or Social Security #

 

		 

 

Second Signature (if purchasing jointly)

 

 

Printed Second Name

 

 

Entity Name

 

 

Address

 

 

City, State and Zip Code

 

 

Telephone—Business

 

 

Facsimile—Business

 

 

Tax ID # or Social Security #

	

 

Name in which securities should be issued: 

 

Leerink Swann & Company Account Number: 

 

  

This Subscription Agreement is agreed to and accepted as of                 
        , 2001.

 

		 BIOJECT MEDICAL TECHNOLOGIES INC.

 

		 By:

 

		 

 

		 Name: James C. O’Shea

		 Title: Chairman and Chief Executive Officer

 

19

 

 CERTIFICATE OF SIGNATORY

 

(To be completed if Securities are being subscribed for by an entity)

 

                I,           
                                        
    , am the                                   
                                        
     of                                   
                                 (the “Entity”).

 

        I certify that I am empowered and duly authorized by the Entity to execute and carry out the terms of the Subscription
Agreement and to purchase and hold the Securities, and certify further that the Subscription Agreement has been duly and validly executed on behalf of the Entity and constitutes a legal and binding obligation of the Entity.

 

        IN WITNESS WHEREOF, I have set my hand this      day of     
        , 2001.

 

		 

 

		 (Signature)

 

20<PAGE>

                                                                     Exhibit 4.1
                                                                     -----------

                                CARESIDE, INC.
                          DIRECTOR STOCK OPTION PLAN
               (as amended and restated effective May 24, 2001)

1.   Purpose

          The purpose of this Director Stock Option Plan (as amended and
restated effective May 24, 2001) (the "Plan") of CARESIDE, Inc. (the "Company"),
is to encourage ownership in the Company by outside directors of the Company
whose services are considered essential to the Company's continued progress and
thus to provide them with a further incentive to continue to serve as directors
of the Company. The Plan is also intended to assist the Company through
utilization of the incentives provided by the Plan to attract and retain
experienced and qualified candidates to fill vacancies in the Board which might
occur in the future.

2.   Administration

          The Plan will be administered by a committee of the Board of Directors
consisting of those Directors who are not Eligible Directors (as defined below)
and either the Chief Financial Officer of the Company (if not then a Director)
or such other employee of the Company as the Board may designate (the
"Committee"). The Chief Executive Officer shall serve on the Committee. Subject
to the express provisions of the Plan, the Committee will have complete
authority: to interpret the Plan; to prescribe, amend, and rescind rules and
regulations relating to it; to determine the terms and provisions of the
respective option agreements (which need not be identical); and to make all
other determinations necessary or advisable for the administration of the Plan.
The Committee's determination on the matters referred to in this Section 2 will
be conclusive.

3.   Participation in the Plan

          Persons who are now or who hereafter become incumbent directors of the
Company who are not at the time employees of the Company or any subsidiary of
the Company and who have not been nominated to serve as directors pursuant to an
agreement with the Company ("Eligible Directors") shall be eligible to
participate in the Plan. A director of the Company shall not be deemed to be an
employee of the Company solely by reason of the existence of a consulting
contract between such director and the Company or any subsidiary thereof
pursuant to which the director agrees to provide consulting services as an
independent consultant to the Company or its subsidiaries on a regular or
occasional basis for a stated consideration.

4.   Stock Subject to the Plan

          The stock subject to the Plan shall consist of 250,000 shares of
Company's Common Stock, $.01 par value ("Common Stock"). Such shares may, as the
Committee shall
<PAGE>

from time to time determine, be either authorized and unissued shares of Common
Stock or issued shares of Common Stock which have been reacquired by the
Company. If an option shall expire or terminate for any reason without having
been exercised in full, the shares represented by the portion thereof not so
exercised shall (unless the Plan shall have been terminated) become available
for other Options to be granted under the Plan.

5.   Stock Options

          (a)  Option Agreements. Each option granted under this Plan shall be
               -----------------
evidenced by a written agreement in such form as the Committee shall from time
to time approve, which agreements shall comply with and be subject to the terms
and conditions set forth in the Plan.

          (b)  Issuance and Vesting of Options. Each Eligible Director shall be
               -------------------------------
granted under this Plan an option to purchase 5,000 shares of Common Stock in
respect of each calendar year of service as a director commencing before or
after, and ending after, the effective date of the Plan, commencing with the
calendar year ending December 31, 2001, with a one time grant of options for
2,500 shares for 2001 to existing Eligible Directors. Each new Eligible Director
will receive an award of options for 7,500 shares for his or her initial year of
service as a director, with an annual grant of an option to purchase 5,000
shares thereafter. Options hereunder shall be granted by the Board either after
conclusion of or during the year of service as a director to which they relate
and if not granted prior to such date in respect of service for the most
recently completed calendar year shall be automatically awarded for such prior
year as of the date of the Company's annual shareholder's meeting. In the event
a person becomes a director in the middle of a calendar year, such person's
option award for such first partial year shall be prorated so as to relate to
the period such person served as a director in such year. Options granted after
conclusion of a calendar year shall vest upon grant if relating to service as a
director in the calendar year just concluded. Options granted during the year of
service as a director to which they relate shall vest upon December 31 of that
year.

          (c)  Option Price per Share. All options granted hereunder shall be
               ----------------------
exercisable at a price per share equal to the Fair Market Value (as hereafter
defined) of a share of Common Stock on the Date of Grant. For purposes of the
Plan, the term "Fair Market Value" of a share of Common Stock shall mean, as of
the date on which such fair market value is to be determined, the fair market
value as determined by the Committee in such manner as it, in good faith, may
deem appropriate. "Date of Grant" shall mean the earlier of the date an award
for a year of service under the Plan is authorized by the Board or the date of
the Company's annual shareholder's meeting, if no award for the most recently
completely calendar year has been made by the Board prior to such date. If the
Common Stock is at the time of reference publicly traded, the fair market value
shall be the closing price of a share of Common Stock as reported in the Wall
                                                                         ----
Street Journal (or a publication or reporting service deemed equivalent to the
--------------
Wall Street Journal for such purpose by the Committee) for the over-the-counter
-------------------
market or any national securities exchange and other securities market which at
the time are included in the stock price quotations of such publication. If no
such sale is so reported for such date, fair market value shall mean the average
of the latest bid and asked prices so reported for such date. In the event that
the Committee shall determine such stock price quotation is not representative
of fair market

                                       2
<PAGE>

value, the Committee may determine fair market value in such a manner as it
shall deem appropriate under the circumstances. In no event shall the fair
market value of any share of Common Stock be less than its par value.

          (d)  Options Nontransferable. Each option granted under the Plan by
               -----------------------
its terms shall not be transferable by the optionee otherwise than by will, or
by the laws of descent and distribution, or pursuant to a qualified domestic
relations order as defined by the Internal Revenue Code of 1986, as amended, or
Title I of the Employee Retirement Income Security Act, or the rules thereunder,
and shall be exercisable during the lifetime of the optionee only by him. No
option or interest therein may be transferred, assigned, pledged, or
hypothecated by the optionee during his lifetime, whether by operation of law or
otherwise, or be made subject to execution, attachment, or similar process.

          (e)  Accelerated Vesting. Notwithstanding the provisions hereof
               -------------------
specifying the installments in which options shall be exercisable, options shall
become exercisable in full (i) upon the retirement of the director in accordance
with any mandatory retirement policy for members of the Board, which policy may
be established by the Board, (ii) upon the total and permanent disability or
death of the director, or (iii) if any of the following events shall occur: (a)
the Company shall execute a definitive agreement to merge or consolidate with or
into another corporation and the Company shall not be the surviving corporation
in the merger (or shall become a subsidiary of any other corporation party to
such merger agreement, unless such transaction shall involve no significant
change in beneficial ownership of the Company) and the stockholders of the
Company shall have approved the terms of such agreement; (b) the Company shall
enter into a definitive agreement to sell or otherwise dispose of all or
substantially all of its assets and the stockholders of the Company shall have
approved the terms of such agreement; or (c) any person or group shall acquire,
or increase its ownership to, more than 20% of the Company's then outstanding
voting stock.

          (f)  Expiration of Options. No option shall be exercisable after the
               ---------------------
expiration of the earlier of (i) five years from the date when such option was
granted or (ii) three years following (x) the retirement or resignation of the
optionee as a director of the Company, or (y) the failure of the optionee to be
reelected a director of the Company, or (z) the total and permanent disability
or death of the optionee.

          (g)  Exercise of Options. Options may be exercised only by notice to
               -------------------
the Company, accompanied by payment of the full purchase price for the shares as
to which they are exercised, as well as any federal, state, and/or local income
tax withholding required in connection with the exercise. Such purchase price,
together with any income tax withholding amount required, shall be paid in full
upon any exercise of an option (i) by cash including a personal check payable to
the order of the Company or (ii) by delivering an amount having an aggregate
Fair Market Value (as of the date of delivery) equal to the aggregate exercise
price of Common Stock already owned by the optionee, or (iii) by any combination
of (i) and (ii). Shares which otherwise would be delivered to the holder of an
option exercise may, at the election of the holder, be retained by the Company
in payment of any federal, state, and/or local income tax withholding due in
connection with an exercise, and shall be valued at fair market value as of the
date of exercise; provided, however, that the payment of any amount of
withholding tax by an

                                       3
<PAGE>

optionee with shares of Common Stock (whether already owned by the optionee or
retained by the Company from the number of shares otherwise deliverable to the
optionee upon exercise) shall be subject to any restrictions set forth in the
related option agreement.

          (h)  Nonstatutory Options. No option granted under the Plan shall
               --------------------
constitute an "incentive stock option" as that term is defined in the Internal
Revenue Code of 1986.

6.   Modification, Extension, and Renewal of Options

          The Committee shall have the power to modify, extend or renew
outstanding options and authorize the grant of new options in substitution
therefor, provided that such power may not be exercised in a manner which would
(i) alter or impair any rights or obligations under any option previously
granted without the written consent of the optionee or (ii) adversely affect the
qualification of the Plan or any other stock-related plan of the Company under
Rule 16b-3 under the Securities Exchange Act of 1934 or any successor provision.

7.   Assignment

          The rights and benefits under this Plan may not be assigned and any
attempted assignment of such rights and benefits shall be null and void.

8.   Limitation of Rights

          (a)  No Right to Continue as a Director. Neither the Plan, nor the
               ----------------------------------
granting of an option nor any other action taken pursuant to the Plan, shall
constitute or be evidence of any agreement or understanding, express or implied,
that the Company will retain a director for any period of time, or at any
particular rate of compensation.

          (b)  No Stockholder's Rights for Optionees. An optionee or his
               -------------------------------------
representative shall have no rights as a stockholder with respect to the shares
covered by his option until the date of the issuance to him or his
representative of a stock certificate therefor, and no adjustment will be made
for dividends or other rights for which the record date is prior to the date
such certificate is issued.

9.   Changes in Present Stock

          In the event of any merger, consolidation, reorganization,
recapitalization, stock dividend, stock split or other change in the corporate
structure or capitalization affecting the Company's present Common Stock,
appropriate adjustment shall be made by the Committee in the number and kind of
shares which are or may become subject to options granted or to be granted
hereunder and the per share option price to be paid therefor.

                                       4
<PAGE>

10.  Effective Date and Duration of the Plan

          Options shall be granted under the Plan, subject to its authorization
and adoption by the Stockholders of the Company, at any time or from time to
time after its adoption by the Board of Directors, but no option shall be
exercisable under the Plan until the Plan shall have been adopted and approved
at the annual meeting of stockholders of the Company next following adoption of
the Plan by the Board. In the event the Plan is not so adopted by stockholders,
all options which may have been granted shall be null and void. The Plan shall
terminate on August 31, 2008 (unless earlier discontinued by the Board) but such
termination shall not affect the rights of the holder of any option outstanding
on such date of termination.

11.  Amendment of the Plan

          The Board may suspend or discontinue the Plan or revise or amend it in
any respect whatever; provided, however, that without approval of the
Stockholders no revision or amendment shall change the number of shares subject
to the Plan (except as provided in Section 9), change the definition of the
class of directors eligible to receive options, or materially increase the
benefits accruing to participants under the Plan.

12.  Compliance with Law, etc.

          Notwithstanding any other provision of this Plan or agreements made
pursuant hereto, the Company shall not be required to issue or deliver any
certificate or certificates for shares of Common Stock under this Plan prior to
fulfillment of all of the following conditions:

          (a)  Effectiveness of any registration or other qualification of such
shares or the Company under any state or federal law or regulation which the
Board shall, in its absolute discretion or upon the advice of counsel, deem
necessary or advisable; and

          (b)  Grant of any other consent, approval or permit from any state or
federal governmental agency or securities exchange which the Board shall, in its
absolute discretion or upon the advice of counsel, deem necessary or advisable.

13.  Notice

          Any notice to the Company required by this Plan shall be in writing
addressed to the Secretary of the Company at its principal office, and shall be
deemed delivered only when it is received by the Secretary.

14.  Governing Law

          This Plan and all determinations made and actions taken pursuant
hereto shall be governed by the law of the State of Delaware, and construed
accordingly.

                                       5
<PAGE>

15.  Effective Date

          This Director Stock Option Plan shall be effective from and after the
date of the initial public offering of the Company's Common Stock.

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]